Aura Biosciences Inc. (AURA)
5.71
-0.23 (-3.87%)
At close: Apr 03, 2025, 3:59 PM
5.66
-0.71%
Pre-market: Apr 04, 2025, 04:10 AM EDT
-3.87% (1D)
| Bid | 5.6 |
| Market Cap | 286.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.75 |
| PE Ratio (ttm) | -3.26 |
| Forward PE | -3.87 |
| Analyst | Strong Buy |
| Ask | 5.84 |
| Volume | 328,874 |
| Avg. Volume (20D) | 238,175 |
| Open | 5.63 |
| Previous Close | 5.94 |
| Day's Range | 5.51 - 5.81 |
| 52-Week Range | 5.51 - 12.38 |
| Beta | 0.43 |
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was inc...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 106
Stock Exchange NASDAQ
Ticker Symbol AURA
Website https://www.aurabiosciences.com
Analyst Forecast
According to 5 analyst ratings, the average rating for AURA stock is "Strong Buy." The 12-month stock price forecast is $23.5, which is an increase of 311.92% from the latest price.
Stock Forecasts5 months ago
+14.09%
Aura Biosciences shares are trading higher after H...
Unlock content with
Pro Subscription
5 months ago
+0.39%
Aura Biosciences shares are trading higher after the company announced multiple complete clinical responses following its single low-dose administration of Bel-sar in patients with non-muscle-invasive bladder cancer in its ongoing Phase 1 trial.
